Lumexa Imaging Holdings, Inc. (LMRI) Stock Price & Analysis

Lumexa Imaging Holdings, Inc. (LMRI) closed at USD 11.62 on Wednesday, October 28, 2026, down 0.43% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 11.67; the Oct 28, 2026 session ranged USD 11.46–12 on volume of 210,657 shares. Market capitalization is $1.12B, with a 52-week range of USD 6.45–19.45 (NMS). Source: Nexqual, retrieved October 29, 2026 at 09:09 UTC.

Also available as compact Markdown for AI agents: nexqual.com/LMRI.md

Key facts (LMRI)

• Insider open-market purchases, last ~7 months: 2 Form 4 filings, $477K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.80 on a 1–5 scale) (10 analysts), mean target USD 17.67 (range 13–23).
• Total return with dividends: 1Y -37.3% vs S&P 500 +13.6%; 5Y -37.3% vs S&P 500 +79.8%.
• Next earnings: 2026-11-10, EPS estimate USD 0.18, revenue estimate $270M.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (LMRI)

P/S 1.1x · EV/EBITDA 14.0x · EV/Sales 1.9x · P/FCF 342.8x · P/B 1.8x · FCF yield 0.29% · Earnings yield -0.94% · Net debt $766M · EV $1.88B

Insider purchases (SEC Form 4, open-market, last ~7 months) (LMRI)

2 purchases, $477K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (LMRI)

Consensus Buy (mean 1.80 on a 1–5 scale), 10 analysts; mean target USD 17.67 (low 13, high 23).

Rating changes, last 120 days:

Total return (dividends reinvested) (LMRI)

LMRI earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

LMRI recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

LMRI revenue by business segment (quarter ended Jun 30, 2026)

LMRI revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

LMRI suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 30, 2026.

LMRI company outlook (results filed Aug 12, 2026)

• “Full Year Outlook: Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026. • Reiterating full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion. • Narrowing its full-year 2026 Adjusted EBITDA guidance range to $235 million to $241 million, from its prior range of $234 million to $242 million.”
• “(At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%) • Reiterating guidance for Adjusted EPS of $0.71 to $0.77 per share.”
• “Lumexa Imaging Earnings Conference Call and Webcast Lumexa Imaging will host a conference call to discuss its second quarter 2026 results, as well as its 2026 outlook, on August 12, 2026 at 5:00 p.m.”

Quoted word-for-word from the SEC 8-K results press release.

LMRI analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 09:09 UTC)

Technical Analysis (LMRI)

Nexqual's technical model rates LMRI "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 09:09 UTC.

Analyst Ratings (LMRI)

Wall Street analysts rate LMRI "Buy" based on 10 analysts, with a mean price target of USD 17.67 (range USD 13–23), per Nexqual as of October 29, 2026 at 09:09 UTC.

Earnings (LMRI)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 09:09 UTC.

Financials & Fundamentals (LMRI)

Source: Nexqual, October 29, 2026 at 09:09 UTC.

Financial Health Score (LMRI)

Nexqual rates Lumexa Imaging Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 09:09 UTC.

Ownership (LMRI)

Source: Nexqual, October 29, 2026 at 09:09 UTC.

Leadership (LMRI)

Lumexa Imaging Holdings, Inc. is led by Caitlin Zulla, CEO & Director, per Nexqual as of October 29, 2026 at 09:09 UTC.

Major Backers & Investors (LMRI)

Notable institutional backers of Lumexa Imaging Holdings, Inc. include Brown Advisory Inc., Massachusetts Financial Services Co., Think Investments LP, according to Nexqual as of October 29, 2026 at 09:09 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 09:09 UTC.

From Lumexa Imaging Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• We are one of the largest national providers of diagnostic imaging services.
• Utilizing third-party software allows us to operate more efficiently and to quickly scale, adapt and implement new technology across our platform, including in connection with the integration of newly acquired or de novo centers.
• Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders.
• We have built a diversified network of approximately 102,000 referring physicians, representing more than 32,000 physician practices in 2025.

Partnerships

• We build de novo centers with an average initial capital investment of $4.0 million, targeting annual Adjusted EBITDA contribution of approximately $1.0 million to $3.0 million.
• To further this goal, we have partnered with third-party technology providers to build a scalable clinical technology system with radiology information systems (“RIS”); picture archiving and communication systems (“PACS”); revenue cycle management (“RCM”) systems; and programs designed to increase both efficiency and accuracy in reporting reads.

Legal & Regulatory Risks (Item 1A, quoted)

• Our business may also be affected by state and federal anti-kickback and anti-self-referral laws.
• Our payors require that the radiologists providing imaging services are credentialed, before the payor will commence payment. We have experienced a slowdown in the credentialing of radiologists over the last several years which has lengthened our billing and collection cycle, and could negatively impact our ability to collect revenue from patients covered by Medicare.
• Government authorities or other parties may assert that our business practices violate antitrust laws.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 09:09 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt